spacer
home > ebr > spring 2004 > patently better - the rights and wrongs of patent protection drug discovery technology
PUBLICATIONS
European Biopharmaceutical Review

Patently Better - The Rights and Wrongs of Patent Protection Drug Discovery Technology

Whether to secure development funding, protect product licence fees or simply to stop third parties profiting from the fruits of their research, the patent is an essential business tool for firms in the biopharmaceutical field. This article looks at the essential role that patents play, and explores some important recent changes affecting the availability of patent protection.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gareth Williams is a Patent Attorney and European Trade Mark Attorney at Marks and Clerk. Gareth obtained an honours degree in Biological Sciences from Oxford University, where he remained to complete a doctorate in Molecular Biology and Genetics researching the Y chromosome, funded as part of the Human Genome Project. He entered the patent profession in 1998 and is a qualified UK and European Patent Attorney. He has acted for clients in a variety of fields, but specialises particularly in patent work in the fields of biotechnology, medical devices, business method inventions and mechanical devices. His practice involves the drafting, filing and prosecution of patent applications worldwide, the handling of opposition and appeal work at the European Patent Office, and advice on infringement matters and general intellectual property strategy.

spacer
Gareth Williams
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

THAI Announces Shark Fin-Free Cargo Policy

Thai Airways International Public Company Limited (THAI) announces that the carrier has implemented strict Cargo policy on the shipment prohibition of shark fin on THAI Cargo, effective from 15 July 2014.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

Cancer Vaccines

15-16 September 2014, Holiday Inn Regents Park, London UK

The global therapeutic cancer vaccines market is expected to grow to a value of $7.8 billion by 2019. As companies look to develop new drugs to enter this rapidly growing industry, Cancer Vaccines 2014 will mark the path forward in terms of cancer vaccine research, clinical development and regulation.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement